All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LineaDNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Applied DNA Sciences Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2020
Details:
All animals demonstrated seroconversion to producing IgG against SARS-CoV-2 Spike Protein already by day 14, and significantly enhanced responses by day 38.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-eVax
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Rottapharm Biotech
Deal Size: Undisclosed Upfront Cash: $3.3 million
Deal Type: Collaboration June 04, 2020
Details:
Under the terms of this collaboration, Rottapharm Biotech will provide Takis with operational support, and with the financial resources needed to complete Phase I/II clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
Details:
Researchers at National Institute of Infectious Diseases found that Takis vaccines after a single vaccination developed antibodies in mice that can block the infection of SARS-CoV-2 on human cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2020
Details:
The vaccine developed by ReiThera has been obtained from a fragment of the genetic material of the virus and is based on the technology called electroporation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Linear DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Applied DNA Sciences Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 02, 2020
Details:
Applied DNA is expected to enter large-scale production of candidates in march; preclinical testing in animals by takis biotech anticipated to begin in calendar Q2 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Linear DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Applied DNA Sciences Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2020
Details:
LineaRx, a subsidiary of Applied DNA, will work with Takis Biotech on preclinical development of a linear DNA vaccine based on polymerase chain reaction (PCR).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
